Tolfenamicacid () antibody and antigen (hapten, BSA/OVA conjugated)
Diagnostic anti-Tolfenamicacid antibodies (anti-Tolfenamicacid) and diagnostic hapten-carrier conjugates BSA-Tolfenamicacid, OVA-Tolfenamicacid, KLH-Tolfenamicacid antigens for Inflammation/autoimmune/inflammatory disease Tolfenamicacid detection in ELISA test, competitive ELISA, Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-SMT-197-Ag01 | BSA-Tolfenamicacid | 756 |
GMP-SMT-197-Ag02 | OVA-Tolfenamicacid | 756 |
GMP-SMT-197-Ab01 | Anti-Tolfenamicacid mouse monoclonal antibody (mAb) | 1953 |
GMP-SMT-197-Ab02 | Anti-Tolfenamicacid human monoclonal antibody (mAb) | 1953 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-SMT-197-Ag01 |
Product Name | BSA-Tolfenamicacid |
Target/Biomarker | Tolfenamicacid(NULL) |
Expression platform | Synthetic |
Bioactivity validation | Tolfenamicacid (NULL) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation. |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Tolfenamicacid (NULL) / OVA-Tolfenamicacid (NULL) is Synthetic. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-SMT-197-Ag02 |
Product Name | OVA-Tolfenamicacid |
Target/Biomarker | Tolfenamicacid(NULL) |
Expression platform | Synthetic |
Bioactivity validation | Tolfenamicacid (NULL) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation. |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Tolfenamicacid (NULL) / OVA-Tolfenamicacid (NULL) is Synthetic. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-SMT-197-Ab01 |
Product Name | Anti-Tolfenamicacid mouse monoclonal antibody (mAb) |
Target/Biomarker | Tolfenamicacid(NULL) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Human Tolfenamicacid (NULL) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Tolfenamicacid (NULL) antibodies in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation. |
Tag | mFc |
Products description | Anti-human Tolfenamicacid (NULL) monoclonal antibody (mAb) is a monoclonal antibody produced by hybridoma technology. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-SMT-197-Ab02 |
Product Name | Anti-Tolfenamicacid human monoclonal antibody (mAb) |
Target/Biomarker | Tolfenamicacid(NULL) |
Expression platform | CHO |
Isotypes | Human IgG1 |
Bioactivity validation | Human Tolfenamicacid (NULL) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Tolfenamicacid (NULL) antibodies in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation. |
Tag | mFc |
Products description | Anti-human Tolfenamicacid (NULL) monoclonal antibody (mAb) is a monoclonal antibody produced by hybridoma technology. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
1. Understanding Tolfenamic Acid and Its Role in In Vitro Diagnosis (IVD) Tolfenamic acid, a member of the nonsteroidal anti-inflammatory drug (NSAID) class, exhibits robust anti-inflammatory, analgesic, and antipyretic properties, making it a valuable therapeutic agent in various medical contexts. In the realm of in vitro diagnosis (IVD), Tolfenamic acid plays a critical role as a target molecule for precise detection and quantification. Its molecular structure, consisting of a carboxylic acid group and a heterocyclic aromatic ring, lends itself to specific interactions with antibodies and competitive antigens, enabling accurate measurement in biological samples. Tolfenamic acid is commonly prescribed for the management of pain associated with conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhea, and acute musculoskeletal injuries. Its anti-inflammatory effects stem from the inhibition of cyclooxygenase (COX) enzymes, particularly COX-2, leading to decreased production of pro-inflammatory prostaglandins. Additionally, Tolfenamic acid exhibits analgesic properties by modulating pain signaling pathways in the central nervous system. 2. Significance of Tolfenamic Acid Measurement Measuring Tolfenamic acid levels holds significant clinical and diagnostic implications across various domains: Clinical Assessment: Tolfenamic acid measurement serves as a valuable tool for clinicians in assessing disease severity, monitoring treatment response, and optimizing therapeutic regimens. By quantifying Tolfenamic acid levels in patient samples, healthcare providers can tailor NSAID therapy to individual patient needs, ensuring optimal pain relief and inflammation control while minimizing the risk of adverse effects. Therapeutic Drug Monitoring: Therapeutic drug monitoring (TDM) of Tolfenamic acid levels is essential for maintaining therapeutic efficacy and safety. Monitoring plasma concentrations allows clinicians to adjust dosage regimens based on individual pharmacokinetic parameters, ensuring that patients receive adequate analgesia while minimizing the risk of toxicity or treatment failure. Forensic Utilization: In forensic toxicology, Tolfenamic acid measurement plays a crucial role in determining drug exposure and assessing compliance with prescribed medication regimens. Analysis of Tolfenamic acid levels in biological specimens such as blood, urine, or hair samples can provide valuable information regarding an individual's recent drug use history, aiding in criminal investigations, workplace drug testing, and accident reconstructions. Research Advancements: Tolfenamic acid measurement contributes to ongoing research efforts aimed at elucidating its pharmacokinetic and pharmacodynamic properties, exploring potential drug interactions, and investigating novel therapeutic applications. By furthering our understanding of Tolfenamic acid's mechanisms of action and therapeutic potential, researchers can develop more effective treatment strategies for pain management and inflammation-related disorders. Public Health Implications: Surveillance of Tolfenamic acid levels in population-based studies enables the assessment of NSAID utilization patterns, identification of high-risk populations, and evaluation of associated health outcomes. This information informs public health policies and interventions aimed at promoting safe and appropriate medication use, reducing the burden of pain-related conditions, and improving overall patient care. In summary, the measurement of Tolfenamic acid holds significant clinical, forensic, research, and public health implications, underscoring its importance as a target molecule in in vitro diagnosis. By offering specialized antibodies and competitive antigens tailored for Tolfenamic acid detection, our company empowers healthcare professionals, researchers, and forensic experts to conduct accurate and reliable measurements, ultimately improving patient outcomes and advancing our collective understanding of pain management and inflammatory disorders.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.